CD276 and glioblastoma: CAR T cells targeting B7-H3, CSPG4 and HER2 have also been shown to eliminate both differentiated GBM cells and GBM CICs in preclinical models of GBM (Ahmed et al., 2010; Pellegatta et al., 2018; Nehama et al., 2019).